A randomized, double-blind, placebo-controlled phase III study evaluating efficacy and tolerability of 2 courses of alefacept in patients with chronic plaque psoriasis

National Psoriasis Foundation clinical consensus on psoriasis comorbidities and recommendations for screening

“…The mean weight of patients with psoriasis entering clinical trials is frequently >90 kg. 39,40 Psoriasis was first associated with obesity in several large, epidemiologic studies from Europe. 33,41,42 Recently, a database from the UK has shown the BMI to be elevated in psoriasis patients.…”

Rapid response to alefacept given to patients with steroid resistant or steroid dependent acute graft-versus-host disease: a preliminary report

“…for study 2) of placebo or alefacept in adults with chronic plaque psoriasis, the response to alefacept was significantly better. 19,20 In both studies, onset of response to alefacept treatment (defined as at least 50% reduction of baseline Psoriasis Area and Severity Index (PASI)) began 60 days after the initiation of therapy. I.m.…”

Patterns of Medication Utilization and Costs Associated with the Use of Etanercept, Adalimumab, and Ustekinumab in the Management of Moderate-to-Severe Psoriasis

“…17 Although the standard approved dosing regimens of these biologic agents have been established in large, randomized, double-blind, placebo-controlled clinical trials, clinical experience in real-world practice settings suggests that off-label dosing regimens are frequently used and clinically relevant. [18][19][20][21][22][23][24][25][26] Off-label dosing regimens can be broadly categorized as dose escalations, dose reductions, intermittent therapy, or interruptions in therapy followed by retreatment. 18 The reasons for these dose adjustments may be to improve efficacy in very…”